CMR phenotypes and clinical outcomes in NYHA class I versus II-IV hypertrophic cardiomyopathy: identifying high-risk asymptomatic patients

Back

ESC Professional Premium Access

CMR phenotypes and clinical outcomes in NYHA class I versus II-IV hypertrophic cardiomyopathy: identifying high-risk asymptomatic patients

Session: Hypertrophic cardiomyopathy: risk prediction and outcomes

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor D. Labib (Calgary, CA)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Dina Labib

Libin Cardiovascular Institute Of Alberta, Calgary (Canada)

0 follower

6 more presentations in this session

High-intensity exercise-related sudden cardiac death in hypertrophy cardiomyopathy

Speaker: Doctor H. Lee (Seoul, KR)

One-year outcomes of patients with hypertrophic cardiomyopathy according to levels of inflammatory biomarkers

Speaker: Doctor M. Golino (Richmond, US)

The relationship between serum lumican levels and myocardial fibrosis in patients with hypertrophic cardiomyopathy

Speaker: Doctor E. Hancioglu (Hatay, TR)

Invasive quantitative assessment of coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy

Speaker: Doctor M. Marques Antunes (Lisboa, PT)

Prolonged ventricular activation time as a novel biomarker identifying burn-out phase of hypertrophic cardiomyopathy

Speaker: Doctor K. Fragkiadakis (Heraklion, GR)

Access the full session

Hypertrophic cardiomyopathy: risk prediction and outcomes

Speakers: Doctor D. Labib, Doctor H. Lee, Doctor M. Golino, Doctor E. Hancioglu, Doctor M. Marques Antunes...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources